Y-mAbs Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2015-04-01
- Employees
- 100
- Market Cap
- $676.1M
- Website
- http://www.ymabs.com
- Introduction
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Naxitamab for High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 122
- Registration Number
- NCT03363373
- Locations
- ๐ฌ๐ง
University Hospital Southampton, Southampton, United Kingdom
๐บ๐ธUniversity of Florida, Gainesville, Florida, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
- Conditions
- CNS MetastasesLeptomeningeal MetastasesNeuroblastoma
- Interventions
- Biological: 131I-omburtamab
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 52
- Registration Number
- NCT03275402
- Locations
- ๐บ๐ธ
Childrens Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธM.D. Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธRiley Hospital for Children, Indianapolis, Indiana, United States
Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
- Conditions
- Brain CancerBrain Stem Glioma
- Interventions
- Radiation: External Beam Radiotherapy
- First Posted Date
- 2012-01-02
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT01502917
- Locations
- ๐บ๐ธ
Weill Medical College of Cornell University, New York, New York, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum
- Conditions
- Peritoneal Cancer
- Interventions
- Biological: 131 I-8H9
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 54
- Registration Number
- NCT01099644
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
- Conditions
- SarcomaBrain and Central Nervous System TumorsNeuroblastoma
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 177
- Registration Number
- NCT00089245
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States